

Influence of salt supplementation on drug therapy in children with congenital adrenal hyperplasia (CAH) due to 21 hydroxylase deficiency aged 0-3 years: Update on a retrospective multicentre analysis using the International-CAH (I-CAH) registry

Uta Neumann¹, Annelieke van der Linde², Ruth Krone³, Ayla Guven⁴, Tülay Güran⁵, Heba Elsedfy⁶, Feyza Darendeliler⁷, Tania Bachega⁸, Antonio Balsamo⁹, Sabine Hannema¹⁰, Niels Birkebaek¹¹, Ana Vieites¹², Carlo Acerini¹³, Martine Cools¹⁴, Tatjana Milenkovic¹⁵, Walter Bonfig¹⁶, Eduardo Correa Costa¹⁷, Navoda Atapattu¹⁸, Liat de Vries¹⁹, Guilherme Guaragna Filho²⁰, Marta Korbonits²¹, Klaus Mohnike²², Jillian Bryce²³, Faisal Ahmed²³, Bernard Voet²⁴, Oliver Blankenstein¹, Hedi Claahsen van der Grinten²

¹Charité Universitätsmedizin Berlin, ²Radboud University Nijmegen, ³University of Birmingham, ⁴Saglik Bilimleri University Istanbul, ⁵Marmara University Istanbul, ⁶Ain Shams University Cairo, ⁷University of Istanbul, ⁸Sao Paulo University, ⁹University of Bologna, ¹⁰Leiden University, ¹¹Aarhus University, ¹²Centro de Investigaciones Endocrinológicas Buenos Aires, ¹³University of Cambridge, ¹⁴University of Ghent, ¹⁵University of Belgrade, ¹⁶University of Munich, ¹⁷Hospital de Clínicas de Porto Alegre, ¹⁸The Central Hospital Colombo, ¹⁹Tel Aviv University, ²⁰Catholic University Porto Alegre, ²¹Queen Mary University of London, ²²Otto-von-Guericke Universität Magdeburg, ²³University of Glasgow, ²⁴Voet Consulting Berlin.

Introduction

Early treatment of classic congenital adrenal hyperplasia (21-hydroxylase deficiency) with glucocorticoids and mineralocorticoids will prevent life-threatening crisis. In some centres, additional salt is prescribed in the first year. However, until now the use of salt is controversial and the benefit has not been proven in studies.


Objectives

To evaluate the effect of additional salt supplementation on fludrocortisone (FC) dosage, hydrocortisone (HC) dosage, height and blood pressure in young CAH-children (0 – 3 yrs).


Conclusion

- Additional salt supplementation during the first year of life in CAH patients reduced FC-dose until 136 days and might reduce the risk of systolic hypertension. Although all CAH children showed a high percentage of hypertensive blood pressure readings, possibly due to FC-therapy or measurement method in young children.
- Independent from salt treatment there is a risk of decreased height gain and increasing BMI in all CAH children from 0-3 years of age which should imply further studies on HC-treatment and dosage in young children with CAH.

Methods



Results



Contact:
Uta.neumann@charite.de
Annelieke.vanderLinde@radboudumc.nl

